Review
Copyright ©The Author(s) 2021.
World J Diabetes. Oct 15, 2021; 12(10): 1655-1673
Published online Oct 15, 2021. doi: 10.4239/wjd.v12.i10.1655
Table 2 Studies and trials with antagonists/inhibitors of nucleic acid sensors and their signaling mediators in various autoimmune diseases
No.
Inhibitor
Disease
Target
Phase (Preclinical/Clinical-trial ID)
Ref.
1Hydroxychloroquine Rheumatoid arthritis and SLETLR7, TLR9, cGAS-STING NCT0380218 (Ongoing Trial)[139]
2SM934SLETLR7 and TLR9NCT03951259 (Phase II)[125]
3AmlexanoxT2DTBK1 and IKKε NCT01975935 (Phase II)[140]
4TJ-M2010-6T1DMyd88Preclinical[129]
5ST-2825SLEIRAK1 and IRAK4Preclinical[126]
6AspirinAGScGASPreclinical[141]
7ODN-1411Rheumatoid ArthritisTLR8Preclinical[142]
8INH-ODNsSLETLR3 and TLR9Preclinical[143]
9X6Autoimmune myocarditiscGASPreclinical[144]
10PF-06650833Rheumatoid ArthritisIRAK4NCT02996500 (Phase II)[127]
11Compound IISLE and AGSTBK1Preclinical[128]
12Sifalimumab (MEDI-545)SLEIFN-αNCT00979654 (Phase II)[145]
13AGS-009SLE and Rheumatoid ArthritisIFN-αNCT00960362 (Phase I)[132]
14IMO-8400Plaque PsoriasisTLR-7, 8, and 9NCT01899729 (Phase IIa)[122]
15CpG-52364SLETLR-7, 8, and 9NCT00547014 (Phase I)[116]